PDCD1 and hepatocellular carcinoma: A previous study revealed that HCC patients benefited from the administration of immune checkpoint inhibitors (ICIs), such as anti-PD-1, anti-PD-L1, and anti-CTLA-4, leading to FDA approval of immunotherapy as a first-line or second-line treatment [28].